OBI Pharma, Inc. (4174) AI Stock Analysis

OBI Pharma, Inc.

(TPEx:4174)

Select Model

Rating:45Neutral

Price Target:TWD 47.00▼(-22.31% Downside)

Action:initiatedcoverage

Date:11/10/26

The score is primarily constrained by extremely weak profitability, cash burn, and balance-sheet deterioration. Positive longer-term technical positioning provides some support, but the negative P/E and lack of dividend yield limit the overall rating.

Positive Factors

Manageable LeverageDebt-to-equity of about 0.27 indicates leverage is currently manageable relative to the company’s capital base. This provides more financial flexibility than a heavily indebted structure, although it does not offset the cash burn or prevent further equity erosion if losses persist.

Negative Factors

Persistent LossesPersistent negative gross profit from 2021 through 2025, alongside very large net losses, shows that OBI Pharma has not established a commercially profitable operating model. The 2025 net margin of about -35% leaves limited evidence that current activities can self-fund growth.

OBI Pharma, Inc. (4174) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 8.58B
Dividend Yield: ―
Average Volume (3M): 1.11M
Price to Earnings (P/E): -2.4
Beta (1Y): 0.22
Revenue Growth: -2.20%
EPS Growth: 29.08%
Country: TW
Employees: 260
Sector: General
Sector Strength: 55
Industry: Biotechnology

OBI Pharma, Inc. Business Overview & Revenue Model

Company Description

OBI Pharma, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing cutting-edge therapies for critical medical needs, specifically in the field of cancer, with operations spanning Taiwan and international markets. The company's...

OBI Pharma, Inc. Financial Statement Overview

Summary

Revenue grew 18.8%, but severe operating and net losses, deeply negative margins, negative operating and free cash flow, and substantial equity erosion indicate very weak financial performance. Low leverage provides limited support.

Income Statement

5Very Negative

Balance Sheet

45Neutral

Cash Flow

7Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Mar 2024	Dec 2022	Dec 2021
Income Statement
Total Revenue	52.20M	58.58M	62.68M	41.55M	4.71M	18.77M
Gross Profit	-135.14M	-77.53M	-76.27M	-73.50M	-40.14M	-25.59M
EBITDA	-1.38B	-1.94B	-2.26B	-1.02B	-1.67B	-1.52B
Net Income	-1.53B	-2.05B	-2.31B	-1.05B	-1.90B	-1.72B
Balance Sheet
Total Assets	2.69B	3.42B	5.65B	5.60B	6.63B	4.49B
Cash, Cash Equivalents and Short-Term Investments	496.96M	1.19B	3.13B	2.78B	4.77B	2.65B
Total Debt	446.14M	515.68M	505.17M	501.05M	247.09M	293.03M
Total Liabilities	495.56M	696.13M	833.38M	650.45M	497.57M	615.95M
Stockholders Equity	1.49B	1.89B	3.81B	3.81B	4.63B	2.72B
Cash Flow
Free Cash Flow	-1.55B	-2.07B	-1.95B	-1.76B	-1.92B	-1.31B
Operating Cash Flow	-1.53B	-2.02B	-1.83B	-1.65B	-1.62B	-1.06B
Investing Cash Flow	629.78M	908.93M	483.02M	-2.80B	-169.89M	82.68M
Financing Cash Flow	69.63M	141.63M	2.17B	607.07M	4.01B	163.75M

OBI Pharma, Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4174 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:1734	64Neutral	TWD 6.07B	17.33	―	3.13%	2.44%	-3.96%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4157	52Neutral	TWD 5.78B	37.38	―	―	530.40%	―
TW:4174	45Neutral	TWD 7.23B	-2.37	―	―	-2.20%	29.08%

* General Sector Average

Performance Comparison

TW:4174 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4174	OBI Pharma, Inc.	60.50	11.70	23.98%
TW:1734	Sinphar Pharmaceutical Co. Ltd.	30.15	1.76	6.19%
TW:4157	TaiGen Biopharmaceuticals Holdings Limited	8.29	-1.23	-12.92%
TW:6976	Acepodia, Inc.	12.00	-3.30	-21.57%
TW:7754	Annji Pharmaceutical Co., Ltd.	69.40	24.75	55.45%
TW:7876	Obigen Pharma, Inc.	66.20	29.51	80.45%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

OBI Pharma, Inc. AI Stock Analysis